Biotech | May 16, 2022
Antengene announces commercial availability of Xpovio in China
The drug will be available in 600 hospitals and 105 DTPs
The drug will be available in 600 hospitals and 105 DTPs
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The investment will accelerate the overall Sarclisa development program
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Owkin builds best-in-class predictive biomedical AI models and robust data sets
Subscribe To Our Newsletter & Stay Updated
